← Back to Search

Other

LY3502970 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have a body mass index (BMI) of ≥30-kilogram square meter (kg/m²)
Have a BMI ≥27 kg/m² and <30 kg/m² with at least 1 of the following weight-related comorbidities eg; [Have hypertension, or dyslipidemia, cardiovascular disease]
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 36
Awards & highlights

Study Summary

This trial is testing a new drug to see if it can help people who are obese or overweight.

Eligible Conditions
  • Obesity

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 36
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 36 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Change From Baseline in BMI in LY3502970 and Placebo
Change From Baseline in Body Weight in LY3502970 and Placebo
Change From Baseline in Waist Circumference in LY3502970 and Placebo
+3 more

Side effects data

From 2022 Phase 2 trial • 383 Patients • NCT05048719
34%
Nausea
28%
Vomiting
15%
Diarrhoea
13%
Constipation
9%
Lipase increased
9%
Flatulence
6%
Gastrooesophageal reflux disease
6%
Abdominal pain upper
6%
Eructation
6%
Dyspepsia
6%
Back pain
4%
Upper respiratory tract infection
4%
Decreased appetite
4%
Abdominal distension
4%
Covid-19
4%
Headache
4%
Sinus tachycardia
4%
Dizziness
4%
Weight decreased
2%
Paraesthesia
2%
Dehydration
2%
Varices oesophageal
2%
Gastrointestinal haemorrhage
2%
Pylorospasm
2%
Urinary tract infection
2%
Arthralgia
2%
Pancreatitis acute
2%
Appendicitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
24 mg LY3502970
36 mg LY3502970 - 1
Placebo
45 mg LY3502970 - 2
45 mg LY3502970 - 1
12 mg LY3502970
3 mg LY3502970
1.5 mg Dulaglutide
36 mg LY3502970 - 2

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: 45 mg-2 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Group II: 45 mg-1 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally once daily until 36 weeks.
Group III: 36 mg-2 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Group IV: 36 mg-1 LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally once daily until 36 weeks.
Group V: 24 mg LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally once daily until 36 weeks.
Group VI: 12 milligram (mg) LY3502970Experimental Treatment1 Intervention
Participants received maintenance dose 12 mg with dose escalation starting from 3 mg,6 mg and then 12 mg LY3502970 administered orally once daily until 36 weeks.
Group VII: PlaceboPlacebo Group1 Intervention
Participants received placebo administered orally once daily until 36 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3502970
2021
Completed Phase 2
~1210

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,605 Previous Clinical Trials
3,199,398 Total Patients Enrolled
52 Trials studying Obesity
40,488 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any trial spots left that I could sign up for?

"Although this study is not recruiting at the moment, it was last updated on October 10th, 2022. This information can be found on clinicaltrials.gov. There are 1172 other trials that are actively recruiting patients."

Answered by AI

Does this study have an age limit? If so, what is the maximum age of participants?

"This trial is open to any applicant aged 18 to 75. There are currently 224 other trials ongoing for patients under 18 and 720 for those over 65."

Answered by AI

What risks come with taking LY3502970?

"LY3502970 is still in Phase 2 clinical trials, so there is only limited data supporting its safety. There is currently no data to support its efficacy."

Answered by AI

Who else is applying?

What state do they live in?
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
~78 spots leftby Mar 2025